[EN] HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE DE SIGNALISATION HEDGEHOG
[EN] HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE DE SIGNALISATION HEDGEHOG
The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
本发明提供了一种新型的1,4-二取代邻苯二酮刺猬途径拮抗剂,可用于治疗癌症。
[EN] DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS<br/>[FR] ANTAGONISTES PHTALAZINE DISUBSTITUÉE DE LA VOIE HEDGEHOG
申请人:LILLY CO ELI
公开号:WO2010147917A1
公开(公告)日:2010-12-23
The present invention provides novel 1,4-disubstituted phthalazine of formula (I ) hedgehog pathway antagonists useful in the treatment of cancer.
本发明提供了一种新型的1,4-二取代邻苯二酮(I)的刺猬通路拮抗剂,可用于癌症治疗。
HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS
申请人:REDX PHARMA PLC
公开号:US20160113928A1
公开(公告)日:2016-04-28
This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.